Details about Eline Aas

Access statistics for papers by Eline Aas.

Last updated 2024-10-10. Update your information in the RePEc Author Service.

Short-id: paa10

Working Papers

2022

1. Health Technology Assessment (HTA) of GLP-1 receptor agonists and SGLT-2 inhibitors in combination with metformin as first-line treatment in patient with type 2 diabetes mellitus (T2DM) and established cardiovascular or chronic kidney disease
   HERO Online Working Paper Series, University of Oslo, Health Economics Research Programme

2009

2. Bruk av paneldatametoder til å belyse allmennlegers henvisningsmønster
   HERO Online Working Paper Series, University of Oslo, Health Economics Research Programme
3. Cost-effectiveness of screening for colorectal cancer with once-only flexible sigmoidoscopy and faecal occult blood test
   HERO Online Working Paper Series, University of Oslo, Health Economics Research Programme View citations (2)
4. Pecuniary compensation increases the participation rate in screening for colorectal cancer
   HERO Online Working Paper Series, University of Oslo, Health Economics Research Programme View citations (4)
5. The effect of screening on treatment cost: The case of colorectal cancer
   HERO Online Working Paper Series, University of Oslo, Health Economics Research Programme

Journal Articles

2024

1. A Guide to an Iterative Approach to Model-Based Decision Making in Health and Medicine: An Iterative Decision-Making Framework
   PharmacoEconomics, 2024, 42, (4), 363-371
2. Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?
   PharmacoEconomics, 2024, 42, (6), 679-691

2023

3. General-Purpose Methods for Simulating Survival Data for Expected Value of Sample Information Calculations
   Medical Decision Making, 2023, 43, (5), 595-609

2022

4. An Efficient Method for Computing Expected Value of Sample Information for Survival Data from an Ongoing Trial
   Medical Decision Making, 2022, 42, (5), 612-625 View citations (1)

2021

5. Desloratadine Exposure and Incidence of Seizure: A Nordic Post-authorization Safety Study Using a New-User Cohort Study Design, 2001–2015
   Drug Safety, 2021, 44, (11), 1231-1242

2020

6. A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction
   The European Journal of Health Economics, 2020, 21, (1), 73-84
7. Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach
   The European Journal of Health Economics, 2020, 21, (3), 321-334

2017

8. Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis
   The European Journal of Health Economics, 2017, 18, (4), 405-415
9. Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort
   The European Journal of Health Economics, 2017, 18, (2), 255-267

2016

10. Expected 10-year treatment cost of breast cancer detected within and outside a public screening program in Norway
    The European Journal of Health Economics, 2016, 17, (6), 745-754

2015

11. Comparative Analysis of Treatment Costs in EUROHOPE
    Health Economics, 2015, 24, (S2), 5-22 View citations (4)
12. Modeling and Validating the Cost and Clinical Pathway of Colorectal Cancer
    Medical Decision Making, 2015, 35, (2), 255-265

2009

13. Pecuniary compensation increases participation in screening for colorectal cancer
    Health Economics, 2009, 18, (3), 337-354 View citations (4)

Chapters

2021

1. The Economic Sustainability of the Norwegian Healthcare System
   A chapter in The Sustainability of Health Care Systems in Europe, 2021, vol. 295, pp 81-101

2017

2. The Effect of Education on Health Behavior after Screening for Colorectal Cancer
   A chapter in Human Capital and Health Behavior, 2017, vol. 25, pp 207-242

2014

3. Chapter 10: Policy Implications
   Chapter 10 in The Economics of Social Capital and Health A Conceptual and Empirical Roadmap, 2014, pp 203-217